Tasly Biopharmaceuticals Co., Ltd. | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease	Recruiting	Phase 1	2025-08-19		NCT07128797
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer	Advanced Colorectal Cancer	Not yet recruiting	Phase 2	2025-02-20		NCT06838546
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors	Cancer of the Uterine Cervix, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, hepatocellular carcinoma, intestinal disorder, liver disorder, lung disorder, lung neoplasm, neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, triple-negative breast carcinoma, uterine disorder	Not yet recruiting	Phase 2	2024-12-09		NCT06724263